Cargando…
Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
BACKGROUND: To evaluate the antitumour activity and safety of metronomic cyclophosphamide vs megestrol acetate in progressive and advanced cancer patients having exhausted all effective therapies under standard care. METHODS: Patients were randomly assigned to receive orally metronomic cyclophospham...
Autores principales: | Penel, N, Clisant, S, Dansin, E, Desauw, C, Dégardin, M, Mortier, L, Vanhuyse, M, Bonodeau, F, Fournier, C, Cazin, J-L, Adenis, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856003/ https://www.ncbi.nlm.nih.gov/pubmed/20354522 http://dx.doi.org/10.1038/sj.bjc.6605623 |
Ejemplares similares
-
Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018) -
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013) -
Megestrol acetate in cachexia and anorexia
por: Yeh, Shing-shing, et al.
Publicado: (2006) -
Megestrol Acetate-Induced Symptomatic Hypogonadism in a Male Patient
por: Munshi, Lubna Bashir, et al.
Publicado: (2018) -
Megestrol acetate for cachexia–anorexia syndrome. A systematic review
por: Ruiz‐García, Vicente, et al.
Publicado: (2018)